Elekta outlines margin focus and AI oncology push, shares on Stockholm radar

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-23, 23:01.

Elekta AB (SE0000163628) remains a focused radiation oncology specialist, with its B shares traded on Nasdaq Stockholm in Swedish kronor. The company’s latest quarterly update in late May emphasized operating margin recovery and tighter cost control alongside continued investment in software and AI-supported treatment planning, according to its investor presentation.Elekta Q4 2025/26 results and presentation

What recent results showed

For the financial year 2025/26, Elekta reported mid-single-digit growth in net sales and an improvement in EBIT margin compared with the prior year, as outlined in its year-end report in Stockholm.Elekta annual and sustainability report Management reiterated its focus on raising profitability through cost efficiency and product mix, while maintaining research and development intensity in oncology informatics.

Order intake in key regions such as Europe and Asia remained solid, supported by hospital investments in linear accelerators and related software. Elekta also stressed the importance of service revenue, which tends to be more recurring and less volatile than equipment sales over the cycle, helping to stabilize cash flows.

Analyst and peer context

On the sell-side, analyst coverage referenced by data providers such as MarketScreener shows a mixed but generally constructive stance on Elekta, with several houses rating the stock between Hold and Buy and highlighting execution on margins as a central driver.Analyst consensus on Elekta Some analysts compare the Swedish group with larger peers such as Siemens Healthineers and Varian in terms of installed base and software ecosystem.

Commentary in the international business press has pointed to robust structural demand for precision radiotherapy and oncology IT, driven by aging populations and wider access to cancer care in emerging markets. At the same time, competition on price and performance remains intense, requiring continuous innovation in imaging integration and adaptive therapy capabilities.

How Elekta makes its money

Elekta generates revenue primarily from radiation therapy systems, notably its Versa HD linear accelerator platform, and from related oncology software such as treatment planning and information management solutions. In addition, the company earns recurring income from maintenance, upgrades and training contracts with hospitals and cancer centers worldwide.

Where the shares trade today

The Elekta shares (SE0000163628) trade on Nasdaq Stockholm under the ticker EKTAb; on 2026-06-23, 17:30 local time, the B shares last changed hands around 47.50 SEK according to exchange data.

This text is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities.